A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Conditions:   Hematologic Malignancy;   Myeloid Malignancy Interventions:   Drug: Ruxolitinib;   Drug: Mesna;   Drug: Anti-thymocyte globulin (ATG);   Drug: Cyclosporine;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Methotrexate;   Radiation: Total Body Irradiation (radiation treatment);   Drug: Bone marrow infusion;   Drug: Busulfan;   Drug: Thiotepa Sponsor:   St. Jude Children's Research Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials